Methods of treating hypertriglyceridemia
AssigneeAmarin Pharmaceuticals Ireland Limited
InventorsRene Braeckman, William Stirtan, Paresh Soni
Life of this patent
Estimating the term…
Abstract
In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
Claims23
A method of reducing a C-reactive protein level in a subject having metabolic syndrome and fasting triglycerides of at least 500 mg/dL, the method comprising:
- identifying the subject as having metabolic syndrome;
- identifying the subject as having fasting triglycerides of at least 500 mg/dL;
- and
- orally administering to the subject about 4 g per day of ethyl eicosapentaenoate for a period of time effective to reduce a C-reactive protein (“CRP”) level in the subject.
A method of reducing a C-reactive protein level in a subject on statin therapy who has metabolic syndrome and fasting triglycerides of about 150 mg/dL to 499 mg/dL, the method comprising:
- identifying the subject as having metabolic syndrome and as having fasting triglycerides of about 150 mg/dL to 499 mg/dL;
- and
- thereafter orally administering to the subject about 4 g per day of ethyl eicosapentaenoate for a period of time effective to reduce a C-reactive protein (“CRP”) level in the subject.
A method treating a subject with mixed dyslipidemia and metabolic syndrome on statin therapy, the method comprising:
- identifying the subject as having mixed dyslipidemia and metabolic syndrome;
- and
- thereafter administering to the subject about 4 dosage units per day, each dosage unit comprising about 900 mg to about 1.1 g of ethyl eicosapentaenoate for a period of at least about 12 weeks to effect a reduction in triglycerides.
Dependencies are inferred from the claim text.